RUBICON Share Price | Rubicon Research Ltd Stock Analysis & Recommendation

Q: When is the next results date for Rubicon Research Ltd?

The next results date for Rubicon Research Ltd is scheduled for 03 February 2026.

Q: Should I buy, sell or hold Rubicon Research Ltd?

Based on the information available, Rubicon Research Ltd presents a compelling case for a "Strong Buy" due to its strong long-term fundamental strength, despite some risks associated with its valuation. The company has demonstrated healthy growth in net profit, with an impressive increase of 88.33%, and has shown strong operational metrics, such as a high operating profit to interest ratio and significant earnings before depreciation, interest, and taxes.Additionally, the low Debt to EBITDA ratio indicates a strong ability to service its debt, which is a positive sign for financial stability. However, it's important to consider that the company has a high Price to Book Value ratio, suggesting that it may be considered expensive relative to its book value, which could be a concern for some investors.In summary, if you are looking for a company with solid growth potential and strong financial health, holding or buying Rubicon Research Ltd could be a favorable decision. However, be mindful of the high valuation, as it may pose risks if market conditions change.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

29.1 lacs (520.60%) Volume

Shareholding (Mar 2026)

FII

7.54%

Held by 28 FIIs

DII

10.02%

Held by 11 DIIs

Promoter

59.86%

When is the next results date for Rubicon Research Ltd?

28-Jan-2026

The next results date for Rubicon Research Ltd is 03 February 2026.

View full answer

Which are the latest news on Rubicon Research?

01-Jun-2026

No latest news for Rubicon Research found.

Should I buy, sell or hold Rubicon Research Ltd?

02-Jun-2026

Why is Rubicon Research Ltd falling/rising?

02-Jun-2026

As of 01-Jun, Rubicon Research Ltd's stock price is rising, currently at 1,167.05, reflecting a 16.24% increase. This growth is driven by strong performance metrics, high investor participation, and solid financial fundamentals, including significant profit growth.

View full answer

Compare Rubicon Research with Similar Stocks

Natco Pharma Cohance Life Granules India

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%

Healthy long term growth as Net Sales has grown by an annual rate of 0% and Operating profit at 0%
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.78 times

With a growth in Net Profit of 88.33%, the company declared Outstanding results in Mar 26

Majority shareholders : Promoters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 20,231 Cr (Small Cap)

P/E

78.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.03

Return on Equity

19.14%

Price to Book

14.92

Revenue and Profits:

Net Sales:

514 Cr

(Quarterly Results - Mar 2026)

Net Profit:

77 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

59.67%

6 Months

92.15%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Rubicon Research for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Rubicon Research Ltd is Rated Strong Buy

Rubicon Research Ltd is rated Strong Buy by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 02 June 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

Read full news article

Rubicon Research Ltd Surges on High-Value Trading and Institutional Interest

Rubicon Research Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value on 2 June 2026, registering a robust 5.27% gain. The stock’s remarkable performance is underpinned by strong institutional participation, significant order flow, and a fresh 52-week high, signalling growing investor confidence amid a challenging market backdrop.

Read full news article

Broad-Based Technical Strength Lifts Rubicon Research Ltd to 52-Week High of Rs 1258.2

Surging to an all-time high of Rs 1258.2 on 2 Jun 2026, Rubicon Research Ltd has demonstrated remarkable price momentum, outpacing its sector and defying the broader market's subdued tone. This milestone caps a three-day rally that has delivered a 25.48% gain, underscoring the stock's robust technical backdrop amid a Sensex trading near its 52-week low.

Read full news article

Announcements

Earnings Call Audio Recording

30-May-2026 | Source : BSE

Earnings Call Audio Recording

Announcement under Regulation 30 (LODR)-Newspaper Publication

30-May-2026 | Source : BSE

Rubicon Newspaper Publication under reg 30

Announcement under Regulation 30 (LODR)-Investor Presentation

29-May-2026 | Source : BSE

Investor Presentation

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

EBIT to Interest (avg)

6.10

Debt to EBITDA (avg)

1.50

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

1.16

Tax Ratio

23.02%

Dividend Payout Ratio

0.23%

Pledged Shares

Institutional Holding

17.55%

ROCE (avg)

25.58%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

14.92

EV to EBIT

54.07

EV to EBITDA

47.95

EV to Capital Employed

15.31

EV to Sales

10.94

PEG Ratio

Dividend Yield

ROCE (Latest)

28.31%

ROE (Latest)

19.14%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

Bollinger Bands

Bullish

KST

Dow Theory

Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 12 Schemes (7.14%)

FIIs

Held by 28 FIIs (7.54%)

Promoter with highest holding

General Atlantic Singapore Rr Pte Ltd (35.89%)

Highest Public shareholder

Shivanand Shankar Mankekar Huf (13.54%)

Individual Investors Holdings

2.82%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 29.22% vs -10.33% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 88.33% vs -18.84% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "389.88",
          "val2": "301.71",
          "chgp": "29.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "106.17",
          "val2": "62.24",
          "chgp": "70.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5.40",
          "val2": "7.51",
          "chgp": "-28.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "70.02",
          "val2": "37.18",
          "chgp": "88.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "27.23%",
          "val2": "20.63%",
          "chgp": "6.60%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "614.49",
          "val2": "528.16",
          "chgp": "16.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "142.24",
          "val2": "144.68",
          "chgp": "-1.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "18.06",
          "val2": "16.26",
          "chgp": "11.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "80.96",
          "val2": "89.04",
          "chgp": "-9.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "23.15%",
          "val2": "27.39%",
          "chgp": "-4.24%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "916.20",
          "val2": "773.03",
          "chgp": "18.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "204.48",
          "val2": "208.58",
          "chgp": "-1.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "25.57",
          "val2": "23.51",
          "chgp": "8.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "118.14",
          "val2": "127.27",
          "chgp": "-7.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "22.32%",
          "val2": "26.98%",
          "chgp": "-4.66%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 36.57% vs 50.40% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 83.64% vs 47.63% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,753.96",
          "val2": "1,284.27",
          "chgp": "36.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "400.24",
          "val2": "264.26",
          "chgp": "51.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "42.17",
          "val2": "36.78",
          "chgp": "14.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "246.74",
          "val2": "134.36",
          "chgp": "83.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "22.82%",
          "val2": "20.58%",
          "chgp": "2.24%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

389.88

301.71

29.22%

Operating Profit (PBDIT) excl Other Income

106.17

62.24

70.58%

Interest

5.40

7.51

-28.10%

Exceptional Items

0.00

Standalone Net Profit

70.02

37.18

88.33%

Operating Profit Margin (Excl OI)

27.23%

20.63%

6.60%

Values in Rs Cr.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is 29.22% vs -10.33% in Dec 2025

Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is 88.33% vs -18.84% in Dec 2025

All Quarterly Results

Half Yearly Results Snapshot (Standalone) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

614.49

528.16

16.35%

Operating Profit (PBDIT) excl Other Income

142.24

144.68

-1.69%

Interest

18.06

16.26

11.07%

Exceptional Items

0.00

Standalone Net Profit

80.96

89.04

-9.07%

Operating Profit Margin (Excl OI)

23.15%

27.39%

-4.24%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Half Yearly Results

Nine Monthly Results Snapshot (Standalone) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

916.20

773.03

18.52%

Operating Profit (PBDIT) excl Other Income

204.48

208.58

-1.97%

Interest

25.57

23.51

8.76%

Exceptional Items

0.00

Standalone Net Profit

118.14

127.27

-7.17%

Operating Profit Margin (Excl OI)

22.32%

26.98%

-4.66%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Nine Monthly Results

Annual Results Snapshot (Consolidated) - Mar'26

Mar'26

Mar'25

Change(%)

Net Sales

1,753.96

1,284.27

36.57%

Operating Profit (PBDIT) excl Other Income

400.24

264.26

51.46%

Interest

42.17

36.78

14.65%

Exceptional Items

0.00

Consolidate Net Profit

246.74

134.36

83.64%

Operating Profit Margin (Excl OI)

22.82%

20.58%

2.24%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2026 is 36.57% vs 50.40% in Mar 2025

Consolidated Net Profit

YoY Growth in year ended Mar 2026 is 83.64% vs 47.63% in Mar 2025

All Annual Results

Company CV

About Rubicon Research Ltd

Rubicon Research Ltd

Small Cap

Pharmaceuticals & Biotechnology

Rubicon Research Limited was incorporated on May 6, 1999, as a Private Company as `Rubicon Consultants Private Limited', with the RoC. Subsequently, the Company's name was changed from `Rubicon Consultants Private Limited' to `Rubicon Research Private Limited' to which a fresh Certificate of Incorporation was issued by the RoC dated September 2, 2002.

Company Coordinates

No Company Details Available